+45.5%
UNP vs GSK
+53.4%
-7.9%
-17.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.4% | -2.7% | +2.3% | +0.2% |
| 7D | -0.7% | -4.2% | +3.4% | +0.1% |
| 30D | -1.1% | -7.5% | +6.4% | +0.5% |
| 3M | +7.9% | -3.3% | +11.1% | +8.4% |
| 6M | +14.6% | -9.3% | +24.0% | +16.7% |
| YTD | +26.6% | +1.6% | +25.0% | +25.8% |
| 1Y | +35.6% | +25.5% | +10.1% | +29.1% |
| 3Y | +45.5% | +49.3% | -3.8% | +32.4% |
| All | +45.5% | +53.4% | -7.9% | +32.4% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling